Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0443 • ACR Convergence 2025
Association between pan-immune-inflammation and synovitis as assessed by ultrasound in rheumatoid arthritis
Elvira E Aguilar-Oliva¹, Luis M Amezcua-Guerra², ismael valenzuela³, Carina Soto-Fajardo⁴, Karina Arias⁵, Alejandra Espinosa⁶, Carlos Pineda⁴ and Luis H Silveira⁷, ¹Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, TLALPAN, Distrito Federal, Mexico, ²Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ³Instituto Nacional de Cardiología Ignacio Chávez, TLALPAN, Distrito Federal, Mexico, ⁴National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico City, Mexico, ⁵Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Tlalpan, Distrito Federal, Mexico, ⁶National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Ciudad de México, Mexico, ⁷Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico
Background/Purpose: The pan-immune-inflammation value (PIV) is a novel composite biomarker derived from blood count parameters, reflecting the systemic balance of immune-inflammatory activity. Although it has…
Abstract Number: 0370 • ACR Convergence 2025
Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
Jeffrey Curtis¹, Joshua Baker², Shilpa Venkatachalam³, Sherry Danese⁴, Julie Ulloa⁵ and Ankit Shah⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Global Healthy Living Foundation, New York, NY, ⁴OutcomesInsights, Calabasas, CA, ⁵OutcomesInsights, Calabasas, ⁶SetPoint Medical, Valencia, CA
Background/Purpose: Despite broadening treatment options for RA, several challenges and unmet needs remain. The 2021 ACR guideline for the treatment of RA marked a significant…
Abstract Number: 0210 • ACR Convergence 2025
Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Akhil Sood¹, Srijana Davuluri², Sheila Haidar³, De Suan Huang³, April Ochoa³, Christy Bill¹ and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Stanford Health Care, Palo Alto, CA
Background/Purpose: Despite guideline recommendations, recombinant zoster vaccine (RZV) uptake remains low among immunocompromised individuals younger than 50 years of age, notably those with rheumatoid arthritis…
Abstract Number: 0146 • ACR Convergence 2025
Association between frailty and delirium and hospitalization outcomes among older adults with rheumatic diseases
Bhavik Bansal¹, Yehseo Jung², Abdulla Damluji³, Parag Goyal⁴ and Namrata Singh⁵, ¹UT Southwestern Medical Centre, Dallas, TX, ²University of Washington, Seattle, WA, ³Johns Hopkins, Baltimore, ⁴Weill Cornell, New York, ⁵University of Washington, Bellevue, WA
Background/Purpose: We investigated the association of frailty and delirium, both independently and in combination, with in-hospital mortality and non-routine discharge (i.e. when a patient is…
Abstract Number: 0078 • ACR Convergence 2025
Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
Abstract Number: 0060 • ACR Convergence 2025
Dietary Management of Rheumatoid Arthritis: A Functional Investigation of the Synbiotic Medical Food, SBD121
Ryan Green¹, Daniela Diaz-Infante Morales¹, Alicia Ballok¹, Kristine Kuhn², Christopher Ritchlin³, Mark Charbonneau¹, Eric Schott¹ and Gerardo Toledo¹, ¹Solarea Bio Inc, Waltham, MA, ²²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ³University of Rochester Medical Center, Canandaigua, NY
Background/Purpose: Rheumatoid arthritis (RA), affecting approximately 1% of the global population RA is a leading cause of disability worldwide. Despite available treatments, including methotrexate (MTX)…
Abstract Number: 2683 • ACR Convergence 2025
Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Stevie Barry¹, Katie McMenamin², Austin Wheeler³, Bryant England³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Rui Xiao¹, Sylvanus Toikumo¹⁴, Henry Kranzler¹⁴, Rachel Kember¹⁴, Scott Damrauer¹⁴, Michael Levin¹⁴, Michael George¹, Ted Mikuls³, Joshua Baker¹ and Thomas Riley¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston Medical Center, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…
Abstract Number: 2614 • ACR Convergence 2025
Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
Charles Peterfy, MD, PhD¹, John Tesser², Yaakov Levine³, Melissa Evangelista⁴, Vibeke Strand⁵, Michael Weinblatt⁶ and David Chernoff⁷, ¹Spire Sciences, Inc., Boca Raton, FL, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³SetPoint Medical, Valencia, CA, ⁴SetPoint Medical Corporation, Valencia, CA, ⁵Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷SetPoint Medical, Sausalito, CA
Background/Purpose: Previously reported results from RESET-RA (ClinicalTrials.gov, NCT04539964) showed neuroimmune modulation via electrical stimulation of the left vagus nerve using an implantable device to treat…
Abstract Number: 2284 • ACR Convergence 2025
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure¹, Gurjot Singh², Kim Nguyen², Nirys Mateo Faxas³, Nicole Tejeda⁴, Kimberly Ramirez Bonetti⁵ and Erick Perez Mejias⁴, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, ³Independent Author, Santo Domingo, Dominican Republic, ⁴Independent Author, Cincinnati, ⁵Independent Author, cincinnati, OH
Background/Purpose: Patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) face increased cardiovascular risk. Different biologic disease-modifying antirheumatic drugs (bDMARDs) may have varying…
Abstract Number: 2268 • ACR Convergence 2025
Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
Clementina López Medina¹, Rafaela Ortega-Castro², Francisco Jose Cepas³, Montserrat Robustillo-Villarino⁴, Andres Zuniga-Vera⁴, Ana Martinez-Feito⁵, Ester Costa-Moya⁶, Delia Taverner-Torrent⁶, Luis Sainz Comas⁷, Cesar Diaz-Torne⁷, Virginia Ruiz-Esquide⁸, Cynthia Rojas⁹, Lourdes Martin-de la Sierra Lopez¹⁰, Laura Jimenez-Rodriguez¹⁰, David Velasco-Sanchez¹⁰, Regina Fará Garcia¹¹, Antonio Juan-Mas¹², Marina soledad Moreno Garcia¹³, Ana Valeria Acosta Alfaro¹⁴, Santiago Muñoz¹⁵, Maria Martín López¹⁶, Raquel Zas¹⁷, FRANCISCO JAVIER GODOY NAVARRETE¹⁸, Isabel Anon Onate¹⁹, Fernando Ortiz-Márquez²⁰, Natalia Mena Vázquez²¹, Paula Estrada-Alarcón²², Jerusalén Calvo²³, Alejandro Escudero Contreras²³ and Chamaida Plasencia-Rodríguez²⁴, ¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³University of Cordoba, Cordoba, Spain, ⁴Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁵Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁶Hospital Sant Joan Reus, Reus, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹Hospital Clinic, Barcelona, Spain, ¹⁰Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹¹Hospital Son Llàtzer, Palma, Spain, ¹²Son Llazter University Hospital, Madrid, Spain, ¹³Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁴Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁶Hospital ¹² de Octubre, Madrid, Spain, ¹⁷Hospital Universitario Doce de Octubre, Madrid, Spain, ¹⁸Jaen University Hospital, Spain, Jaen, Spain, ¹⁹Hospital Universitario de Jaén, Jaén, Spain, ²⁰Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²¹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ²⁴Hospital Universitario La Paz, MADRID, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody that contributes to the development of rheumatoid arthritis (RA) and is associated with greater disease severity. Seroconversion of…
Abstract Number: 2252 • ACR Convergence 2025
Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexander Peterson², Alexandra Schmidt², Katherine Wysham³, Aliyah Pabani⁴, Carolyn Presley⁵, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁶, Ariela Orkaby⁷ and Namrata Singh¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Johns Hopkins, Washington, DC, ⁵Ohio State University Medical Center, Columbus, ⁶VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁷VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA
Background/Purpose: Individuals with rheumatoid arthritis (RA) have a higher prevalence of frailty, even at younger ages, compared to the general population1. Among persons with lung…
Abstract Number: 2234 • ACR Convergence 2025
Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis
Cheuk Yin Tam, Ho So and Lai Shan Tam, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: This study compared the impact of achieving early sustained remission (sREM) versus early sustained low disease activity (sLDA) on patient-reported outcomes (PROs) after 5…
Abstract Number: 2104 • ACR Convergence 2025
Pain 0-10 visual analog scale (VAS) and RAPID3 (routine assessment of patient index data) in OA and RA are similar in 2024 to 1979 and 1989
Theodore Pincus¹, Tengfei Li² and Juan Schmukler¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A 1979 report by Huskisson, who developed the 0-10 pain visual analog scale (VAS) , entitled "Another look at osteoarthritis" indicated mean pain VAS…
Abstract Number: 1930 • ACR Convergence 2025
Can a Multinational Awareness Campaign Improve Referral Rates and Reduce Diagnostic Delays in Patients with Chronic Inflammatory Rheumatic Diseases? The Impact of a Prospective Interventional Study
Nelly Ziade¹, Karen Mechleb², Fatima Alnaimat³, Sherif Gamal⁴, Avin Maroof⁵, Bassel Elzorkany⁶, Manal Mashaleh⁷, Manal El Rakawi⁸, Mahmoud Adly⁹, Lina Elkibbi¹⁰, ERRAOUI Mariam¹¹, Krystel Aouad¹², Chafika Haouichat¹³, Nizar Abdullateef¹⁴, ASAL ADNAN RIDHA¹⁵, Fatemah Baron¹⁶ and Ihsane Hmamouchi¹⁷, ¹Department of Rheumatology, Saint-Joseph University and Hotel-Dieu de France, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³The University of Jordan, amman, Jordan, ⁴Cairo University, Cairo, Egypt, ⁵University of Kurdistan Hawler, Erbil, Iraq, ⁶Private (BZRC), Cairo, Egypt, ⁷Al Saudi Hospital, Amman, Jordan, ⁸Djillali Bounaama University Hospital, Algiers, Algeria, Algiers, Algeria, ⁹Ministry of Health, Kuwait, Kuwait, Saad Elabdulla, Kuwait, ¹⁰Specialized Medical Center, Riyadh, Saudi Arabia, Riyadh, Saudi Arabia, ¹¹CHU Agadir, Agadir, Morocco, ¹²Department of Rheumatology, Saint George Hospital University Medical Center, Beirut, Lebanon, ¹³Djillali Bounaama University Hospital, Algiers, Algeria, ¹⁴Baghdad College of Medicine, Baghdad, Iraq, ¹⁵Baghdad Teaching Hospital, Baghdad, Iraq, ¹⁶Al-Jahra Hospital, Kuwait, Kuwait, Kuwait, Kuwait, ¹⁷Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco
Background/Purpose: Delayed diagnosis and treatment in chronic inflammatory rheumatic diseases (CIRDs), including rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA), is associated with…
Abstract Number: 1751 • ACR Convergence 2025
Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study
Gregory McDermott¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Emily Kowalski⁵, Grace Qian⁶, Liya Sisay Getachew⁵, Kevin Mueller⁶, Alene Saavedra⁶, Lauren O'Keeffe⁶, Natalie Davis¹, Alison Puri⁷, Kathleen Vanni⁶, Caleb Bolden⁸, Tina Mahajan⁹, Erica Mulcaire-Jones¹⁰, Neda Kortam¹¹, Pierre Antoine Juge¹², Tracy J. Doyle¹³, Marcy Bolster¹⁴, Kevin Deane¹⁵, Dinesh Khanna¹⁰, Bryant England⁹, Raul San Jose Estepar⁶, George Washko⁶ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, ⁷Boston University, Brookline, MA, ⁸Massachusetts General Hospital, Boston, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹University of Michigan, Ann Arbor, ¹²Hopital Bichat, APHP, Paris, France, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Massachusetts General Hospital, Concord, MA, ¹⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Quantitative computed tomography (QCT) methods using machine learning have been developed to automatically quantify parenchymal lung features on chest CT imaging. QCT can detect…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].